Compare INLX & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INLX | NSRX |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | United States | Israel |
| Employees | N/A | 7 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.1M | 32.2M |
| IPO Year | 2013 | N/A |
| Metric | INLX | NSRX |
|---|---|---|
| Price | $5.84 | $3.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | 2.3K | ★ 40.8K |
| Earning Date | 05-14-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $11,336.00 | N/A |
| Revenue This Year | $16.86 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.31 | $1.98 |
| 52 Week High | $14.57 | $9.99 |
| Indicator | INLX | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.21 | 52.71 |
| Support Level | N/A | $2.04 |
| Resistance Level | $8.52 | $3.58 |
| Average True Range (ATR) | 0.24 | 0.27 |
| MACD | -0.10 | -0.01 |
| Stochastic Oscillator | 8.52 | 37.71 |
Intellinetics Inc is a document service and solutions software company serving both the small-to-medium business and governmental sectors. The company's digital transformation products and services are provided through two reporting segments: Software and Document Services. The Software segment consists of solutions involving software platforms, which allow customers to capture and manage all documents across operations such as scanned hard-copy documents and all digital documents including those from Microsoft Office 365, digital images, audio, video, and emails. The company's Document Services offerings aid clients as a part of their overall document to convert documents from one medium to another. Majority of revenue is from Document Services Segment.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.